MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease
Abstract
:Simple Summary
Abstract
1. Introduction
2. miRNA Differential Expression during Myelomagenesis
3. Circulating miRNAs as Biomarkers in MM Progression
4. Correlation between Circulating miRNA and Biochemical Parameters in MM Patients
4.1. miRNA as New Clinical Biomarkers in MM Therapy
4.2. microRNA as a New Preventive Approach to Detect the Asymptomatic to Symptomatic MM Transition
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Mahindra, A.; Hideshima, T.; Anderson, K.C. Multiple myeloma: Biology of the disease. Blood Rev. 2010, 24, S5–S11. [Google Scholar] [CrossRef]
- Hallek, M.; Bergsagel, P.L.; Anderson, K.C. Multiple myeloma: Increasing evidence for a multistep transformation process. Blood 1998, 91, 3–21. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, B.; Ju, S.; Chu, H.; Shen, X.; Zhang, Y.; Luo, X.; Cong, H. The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma. Oncol. Lett. 2018, 15, 6094–6106. [Google Scholar] [CrossRef] [PubMed]
- Olteanu, H.; Wang, H.-Y.; Chen, W.; McKenna, R.W.; Karandikar, N.J. Immunophenotypic studies of monoclonal gammopathy of undetermined significance. BMC Clin. Pathol. 2008, 8, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kristinsson, S.Y.; Björkholm, M.; Andersson, T.M.-L.; Eloranta, S.; Dickman, P.W.; Goldin, L.R.; Blimark, C.; Mellqvist, U.-H.; Wahlin, A.; Turesson, I.; et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: A population-based study. Haematologica 2009, 94, 1714–1720. [Google Scholar] [CrossRef] [Green Version]
- Gregersen, H.; Ibsen, J.; Mellemkjoer, L.; Dahlerup, J.; Olsen, J.; Sørensen, H.T. Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. Br. J. Haematol. 2001, 112, 353–357. [Google Scholar] [CrossRef] [PubMed]
- Kristinsson, S.Y.; Tang, M.; Pfeiffer, R.M.; Björkholm, M.; Goldin, L.R.; Blimark, C.; Mellqvist, U.-H.; Wahlin, A.; Turesson, I.; Landgren, O. Monoclonal gammopathy of undetermined significance and risk of infections: A population-based study. Haematologica 2012, 97, 854–858. [Google Scholar] [CrossRef] [Green Version]
- Augustson, B.M.; Begum, G.; Dunn, J.A.; Barth, N.J.; Davies, F.; Morgan, G.; Behrens, J.; Smith, A.; Child, J.A.; Drayson, M.T. Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2005, 23, 9219–9226. [Google Scholar] [CrossRef] [PubMed]
- Vacca, A.; Melaccio, A.; Sportelli, A.; Solimando, A.G.; Dammacco, F.; Ria, R. Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: A randomized trial. Clin. Immunol. Orlando Fla. 2018, 191, 110–115. [Google Scholar] [CrossRef] [PubMed]
- Pourhanifeh, M.H.; Mahjoubin-Tehran, M.; Shafiee, A.; Hajighadimi, S.; Moradizarmehri, S.; Mirzaei, H.; Asemi, Z. MicroRNAs and exosomes: Small molecules with big actions in multiple myeloma pathogenesis. IUBMB Life 2020, 72, 314–333. [Google Scholar] [CrossRef]
- Rajkumar, S.V.; Lacy, M.Q.; Kyle, R.A. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev. 2007, 21, 255–265. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, W.; Corrigan-Cummins, M.; Barber, E.A.; Saleh, L.M.; Zingone, A.; Ghafoor, A.; Costello, R.; Zhang, Y.; Kurlander, R.J.; Korde, N.; et al. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. J. Mol. Diagn. JMD 2015, 17, 669–678. [Google Scholar] [CrossRef] [PubMed]
- Jones, C.I.; Zabolotskaya, M.V.; King, A.J.; Stewart, H.J.S.; Horne, G.A.; Chevassut, T.J.; Newbury, S.F. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br. J. Cancer 2012, 107, 1987–1996. [Google Scholar] [CrossRef] [PubMed]
- Kubiczkova, L.; Kryukov, F.; Slaby, O.; Dementyeva, E.; Jarkovsky, J.; Nekvindova, J.; Radova, L.; Greslikova, H.; Kuglik, P.; Vetesnikova, E.; et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 2014, 99, 511–518. [Google Scholar] [CrossRef] [Green Version]
- Calvo, K.R.; Landgren, O.; Roccaro, A.M.; Ghobrial, I.M. Role of microRNAs from monoclonal gammopathy of undetermined significance to multiple myeloma. Semin. Hematol. 2011, 48, 39–45. [Google Scholar] [CrossRef] [Green Version]
- Pichiorri, F.; De Luca, L.; Aqeilan, R.I. MicroRNAs: New Players in Multiple Myeloma. Front. Genet. 2011, 2, 22. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281–297. [Google Scholar] [CrossRef] [Green Version]
- O’Brien, J.; Hayder, H.; Zayed, Y.; Peng, C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol. 2018, 9, 402. [Google Scholar] [CrossRef] [Green Version]
- Yi, R.; Qin, Y.; Macara, I.G.; Cullen, B.R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003, 17, 3011–3016. [Google Scholar] [CrossRef] [Green Version]
- Wilczynska, A.; Bushell, M. The complexity of miRNA-mediated repression. Cell Death Differ. 2015, 22, 22–33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Eulalio, A.; Huntzinger, E.; Nishihara, T.; Rehwinkel, J.; Fauser, M.; Izaurralde, E. Deadenylation is a widespread effect of miRNA regulation. RNA 2009, 15, 21–32. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bushati, N.; Cohen, S.M. microRNA functions. Annu. Rev. Cell Dev. Biol. 2007, 23, 175–205. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Q.; Yan, W.; Bai, Y.; Xu, H.; Fu, C.; Zheng, W.; Zhu, Y.; Ma, J. Synthetic miR-145 mimic inhibits multiple myeloma cell growth in vitro and in vivo. Oncol. Rep. 2015, 33, 448–456. [Google Scholar] [CrossRef] [PubMed]
- Sun, Y.; Pan, J.; Mao, S.; Jin, J. IL-17/miR-192/IL-17Rs regulatory feedback loop facilitates multiple myeloma progression. PLoS ONE 2014, 9, e114647. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.; Li, F.; Saha, M.N.; Abdi, J.; Qiu, L.; Chang, H. miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2015, 21, 2399–2411. [Google Scholar] [CrossRef] [Green Version]
- Lim, L.P.; Lau, N.C.; Garrett-Engele, P.; Grimson, A.; Schelter, J.M.; Castle, J.; Bartel, D.P.; Linsley, P.S.; Johnson, J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433, 769–773. [Google Scholar] [CrossRef]
- Wang, K.; Yuan, Y.; Cho, J.-H.; McClarty, S.; Baxter, D.; Galas, D.J. Comparing the MicroRNA spectrum between serum and plasma. PLoS ONE 2012, 7, e41561. [Google Scholar] [CrossRef] [PubMed]
- Nazarenko, I.; Rupp, A.-K.; Altevogt, P. Exosomes as a potential tool for a specific delivery of functional molecules. Methods Mol. Biol. 2013, 1049, 495–511. [Google Scholar] [CrossRef]
- Whiteside, T.L.; Boyiadzis, M. Response commentary: Exosomes vs microvesicles in hematological malignancies. Leukemia 2017, 31, 2277. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Desantis, V.; Saltarella, I.; Lamanuzzi, A.; Melaccio, A.; Solimando, A.G.; Mariggiò, M.A.; Racanelli, V.; Paradiso, A.; Vacca, A.; Frassanito, M.A. MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance. Int. J. Mol. Sci. 2020, 21, 3084. [Google Scholar] [CrossRef]
- Mathieu, M.; Martin-Jaular, L.; Lavieu, G.; Théry, C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 2019, 21, 9–17. [Google Scholar] [CrossRef] [PubMed]
- McCoy-Simandle, K.; Hanna, S.J.; Cox, D. Exosomes and nanotubes: Control of immune cell communication. Int. J. Biochem. Cell Biol. 2016, 71, 44–54. [Google Scholar] [CrossRef] [Green Version]
- Neven, K.Y.; Nawrot, T.S.; Bollati, V. Extracellular Vesicles: How the External and Internal Environment Can Shape Cell-To-Cell Communication. Curr. Environ. Health Rep. 2017, 4, 30–37. [Google Scholar] [CrossRef]
- Raimondo, S.; Corrado, C.; Raimondi, L.; De Leo, G.; Alessandro, R. Role of Extracellular Vesicles in Hematological Malignancies. BioMed Res. Int. 2015, 2015, 821613. [Google Scholar] [CrossRef] [Green Version]
- Wang, J.; Faict, S.; Maes, K.; De Bruyne, E.; Van Valckenborgh, E.; Schots, R.; Vanderkerken, K.; Menu, E. Extracellular vesicle cross-talk in the bone marrow microenvironment: Implications in multiple myeloma. Oncotarget 2016, 7, 38927–38945. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, J.; Zhang, M.; Wang, C. Circulating miRNAs as diagnostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. J. Clin. Lab. Anal. 2020, 34, e23233. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pichiorri, F.; Suh, S.-S.; Ladetto, M.; Kuehl, M.; Palumbo, T.; Drandi, D.; Taccioli, C.; Zanesi, N.; Alder, H.; Hagan, J.P.; et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl. Acad. Sci. USA 2008, 105, 12885–12890. [Google Scholar] [CrossRef] [Green Version]
- Abdi, J.; Rastgoo, N.; Li, L.; Chen, W.; Chang, H. Role of tumor suppressor p53 and mi-cro-RNA interplay in multiple myeloma pathogenesis. J. Hematol. Oncol. 2017, 10, 169. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jovanović, K.K.; Roche-Lestienne, C.; Ghobrial, I.M.; Facon, T.; Quesnel, B.; Manier, S. Targeting MYC in multiple myeloma. Leukemia 2018, 32, 1295–1306. [Google Scholar] [CrossRef] [PubMed]
- Li, F.; Xu, Y.; Deng, S.; Li, Z.; Zou, D.; Yi, S.; Sui, W.; Hao, M.; Qiu, L. MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma. Oncotarget 2015, 6, 38270–38282. [Google Scholar] [CrossRef] [PubMed]
- Wu, S.; He, X.; Li, M.; Shi, F.; Wu, D.; Pan, M.; Guo, M.; Zhang, R.; Luo, S.; Gu, N.; et al. MiRNA-34a overexpression inhibits multiple myeloma cancer stem cell growth in mice by suppress-ing TGIF2. Am. J. Transl. Res. 2016, 8, 5433–5443. [Google Scholar]
- Liu, N.; Yang, J.; Yuan, R.; Peng, J.; Liu, L.; Guo, X. Effects of miR-181a on the biological function of multiple myeloma. Oncol. Rep. 2019, 42, 291–300. [Google Scholar] [CrossRef]
- Tatekawa, S.; Chinen, Y.; Ri, M.; Narita, T.; Shimura, Y.; Matsumura-Kimoto, Y.; Tsukamoto, T.; Kobayashi, T.; Kawata, E.; Uoshima, N.; et al. Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma. Br. J. Haematol. 2017, 178, 534–546. [Google Scholar] [CrossRef] [PubMed]
- Benetatos, L.; Vartholomatos, G. Deregulated microRNAs in multiple myeloma. Cancer 2012, 118, 878–887. [Google Scholar] [CrossRef] [PubMed]
- Tagliaferri, P.; Rossi, M.; Di Martino, M.T.; Amodio, N.; Leone, E.; Gulla, A.; Neri, A.; Tassone, P. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr. Cancer Drug Targets 2012, 12, 838–846. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bi, C.; Chng, W.J. MicroRNA: Important player in the pathobiology of multiple myeloma. BioMed Res. Int. 2014, 2014, 521586. [Google Scholar] [CrossRef] [PubMed]
- Grasedieck, S.; Sorrentino, A.; Langer, C.; Buske, C.; Döhner, H.; Mertens, D.; Kuchenbauer, F. Circulating microRNAs in hematological diseases: Principles, challenges, and perspectives. Blood 2013, 121, 4977–4984. [Google Scholar] [CrossRef]
- Zhang, J.; Xiao, X.; Liu, J. The role of circulating miRNAs in multiple myeloma. Sci. China Life Sci. 2015, 58, 1262–1269. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J.J.; Lötvall, J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9, 654–659. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hunter, M.P.; Ismail, N.; Zhang, X.; Aguda, B.D.; Lee, E.J.; Yu, L.; Xiao, T.; Schafer, J.; Lee, M.-L.T.; Schmittgen, T.D.; et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 2008, 3, e3694. [Google Scholar] [CrossRef] [Green Version]
- Xu, P.; Xia, T.; Ling, Y.; Chen, B. MiRNAs with prognostic significance in multiple myeloma: A systemic review and meta-analysis. Medicine 2019, 98, e16711. [Google Scholar] [CrossRef] [PubMed]
- Hermeking, H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010, 17, 193–199. [Google Scholar] [CrossRef] [PubMed]
- Welch, C.; Chen, Y.; Stallings, R.L. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007, 26, 5017–5022. [Google Scholar] [CrossRef] [Green Version]
- Li, Z.; Liu, Z.M.; Xu, B.H. A meta-analysis of the effect of microRNA-34a on the progression and prognosis of gastric cancer. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 8281–8287. [Google Scholar] [CrossRef]
- Di Martino, M.T.; Leone, E.; Amodio, N.; Foresta, U.; Lionetti, M.; Pitari, M.R.; Cantafio, M.E.; Gullà, A.; Conforti, F.; Morelli, E.; et al. Synthetic miR-34a mimics as a novel thera-peutic agent for multiple myeloma: In vitro and in vivo evidence. Clin. Cancer Res. 2012, 18, 6260–6270. [Google Scholar] [CrossRef] [Green Version]
- Zhang, S.; Li, D.; Jiao, G.-J.; Wang, H.-L.; Yan, T.-B. miR-185 suppresses progression of Ewing’s sarcoma via inhibiting the PI3K/AKT and Wnt/β-catenin pathways. OncoTargets Ther. 2018, 11, 7967–7977. [Google Scholar] [CrossRef] [Green Version]
- Manier, S.; Liu, C.-J.; Avet-Loiseau, H.; Park, J.; Shi, J.; Campigotto, F.; Salem, K.Z.; Huynh, D.; Glavey, S.V.; Rivotto, B.; et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood 2017, 129, 2429–2436. [Google Scholar] [CrossRef]
- Frassanito, M.A.; Desantis, V.; Di Marzo, L.; Craparotta, I.; Beltrame, L.; Marchini, S.; Annese, T.; Visino, F.; Arciuli, M.; Saltarella, I.; et al. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes. J. Pathol. 2019, 247, 241–253. [Google Scholar] [CrossRef]
- Georgescu, M.-M. PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer 2010, 1, 1170–1177. [Google Scholar] [CrossRef]
- Hao, M.; Zang, M.; Zhao, L.; Deng, S.; Xu, Y.; Qi, F.; An, G.; Qin, Y.; Sui, W.; Li, F.; et al. Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis. Oncotarget 2016, 7, 19589–19600. [Google Scholar] [CrossRef] [Green Version]
- Huang, J.; Yu, J.; Li, J.; Liu, Y.; Zhong, R. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma. Med. Oncol. 2012, 29, 2402–2408. [Google Scholar] [CrossRef]
- Rocci, A.; Hofmeister, C.C.; Geyer, S.; Stiff, A.; Gambella, M.; Cascione, L.; Guan, J.; Benson, D.M.; Efebera, Y.A.; Talabere, T.; et al. Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia 2014, 28, 1922–1926. [Google Scholar] [CrossRef] [Green Version]
- Raimondi, L.; De Luca, A.; Morelli, E.; Giavaresi, G.; Tagliaferri, P.; Tassone, P.; Amodio, N. MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment. BioMed Res. Int. 2016, 2016, 6504593. [Google Scholar] [CrossRef] [Green Version]
- Amodio, N.; Bellizzi, D.; Leotta, M.; Raimondi, L.; Biamonte, L.; D’Aquila, P.; Di Martino, M.T.; Calimeri, T.; Rossi, M.; Lionetti, M.; et al. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle Georget. Tex. 2013, 12, 3650–3662. [Google Scholar] [CrossRef] [Green Version]
- Vacca, A.; Ria, R.; Semeraro, F.; Merchionne, F.; Coluccia, M.; Boccarelli, A.; Scavelli, C.; Nico, B.; Gernone, A.; Battelli, F.; et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 2003, 102, 3340–3348. [Google Scholar] [CrossRef] [Green Version]
- Moschetta, M.; Mishima, Y.; Kawano, Y.; Manier, S.; Paiva, B.; Palomera, L.; Aljawai, Y.; Calcinotto, A.; Unitt, C.; Sahin, I.; et al. Targeting vasculogenesis to prevent progression in multiple myeloma. Leukemia 2016, 30, 1103–1115. [Google Scholar] [CrossRef]
- Solimando, A.G.; Da Vià, M.C.; Leone, P.; Borrelli, P.; Croci, G.A.; Tabares, P.; Brandl, A.; Di Lernia, G.; Bianchi, F.P.; Tafuri, S.; et al. Halting the vicious cycle within the multiple myeloma ecosystem: Blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression. Haematologica 2020. [Google Scholar] [CrossRef]
- Leone, P.; Di Lernia, G.; Solimando, A.G.; Cicco, S.; Saltarella, I.; Lamanuzzi, A.; Ria, R.; Frassanito, M.A.; Ponzoni, M.; Ditonno, P.; et al. Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients. Oncoimmunology 2019, 8, e1486949. [Google Scholar] [CrossRef] [Green Version]
- Kohlhapp, F.J.; Mitra, A.K.; Lengyel, E.; Peter, M.E. MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene 2015, 34, 5857–5868. [Google Scholar] [CrossRef] [Green Version]
- Di Lernia, G.; Leone, P.; Solimando, A.G.; Buonavoglia, A.; Saltarella, I.; Ria, R.; Ditonno, P.; Silvestris, N.; Crudele, L.; Vacca, A.; et al. Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. J. Clin. Med. 2020, 9, 552. [Google Scholar] [CrossRef] [Green Version]
- Raimondi, L.; Amodio, N.; Di Martino, M.T.; Altomare, E.; Leotta, M.; Caracciolo, D.; Gullà, A.; Neri, A.; Taverna, S.; D’Aquila, P.; et al. Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity. Oncotarget 2014, 5, 3039–3054. [Google Scholar] [CrossRef] [Green Version]
- Martin, S.K.; Diamond, P.; Gronthos, S.; Peet, D.J.; Zannettino, A.C.W. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 2011, 25, 1533–1542. [Google Scholar] [CrossRef] [Green Version]
- Roccaro, A.M.; Sacco, A.; Thompson, B.; Leleu, X.; Azab, A.K.; Azab, F.; Runnels, J.; Jia, X.; Ngo, H.T.; Melhem, M.R.; et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009, 113, 6669–6680. [Google Scholar] [CrossRef]
- Lamanuzzi, A.; Saltarella, I.; Desantis, V.; Frassanito, M.A.; Leone, P.; Racanelli, V.; Nico, B.; Ribatti, D.; Ditonno, P.; Prete, M.; et al. Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma. Oncotarget 2018, 9, 20563–20577. [Google Scholar] [CrossRef] [Green Version]
- Wu, S.; Yu, W.; Qu, X.; Wang, R.; Xu, J.; Zhang, Q.; Xu, J.; Li, J.; Chen, L. Argonaute 2 promotes myeloma angiogenesis via microRNA dysregulation. J. Hematol. Oncol. 2014, 7, 40. [Google Scholar] [CrossRef] [Green Version]
- Li, Y.; Zhang, B.; Li, W.; Wang, L.; Yan, Z.; Li, H.; Yao, Y.; Yao, R.; Xu, K.; Li, Z. MiR-15a/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma. Leuk. Res. 2016, 49, 73–79. [Google Scholar] [CrossRef]
- Rossi, M.; Amodio, N.; Di Martino, M.T.; Tagliaferri, P.; Tassone, P.; Cho, W.C. MicroRNA and multiple myeloma: From laboratory findings to translational therapeutic approaches. Curr. Pharm. Biotechnol. 2014, 15, 459–467. [Google Scholar] [CrossRef]
- Yusnita, Y.; Norsiah, M.D.; Zakiah, I.; Chang, K.M.; Purushotaman, V.S.; Zubaidah, Z.; Jamal, R. MicroRNA (miRNA) expression profiling of peripheral blood samples in multiple myeloma patients using microarray. Malays. J. Pathol. 2012, 34, 133–143. [Google Scholar]
- Hao, M.; Zang, M.; Wendlandt, E.; Xu, Y.; An, G.; Gong, D.; Li, F.; Qi, F.; Zhang, Y.; Yang, Y.; et al. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int. J. Cancer 2015, 136, 1835–1844. [Google Scholar] [CrossRef] [Green Version]
- Hussain, A.; Almenfi, H.F.; Almehdewi, A.M.; Hamza, M.S.; Bhat, M.S.; Vijayashankar, N.P. Laboratory Features of Newly Diagnosed Multiple Myeloma Patients. Cureus 2019, 11, e4716. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yu, J.; Qiu, X.; Shen, X.; Shi, W.; Wu, X.; Gu, G.; Zhu, B.; Ju, S. miR-202 expression concentration and its clinical significance in the serum of multiple myeloma patients. Ann. Clin. Biochem. 2014, 51, 543–549. [Google Scholar] [CrossRef] [Green Version]
- Yoshizawa, S.; Ohyashiki, J.H.; Ohyashiki, M.; Umezu, T.; Suzuki, K.; Inagaki, A.; Iida, S.; Ohyashiki, K. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J. 2012, 2, e53. [Google Scholar] [CrossRef] [Green Version]
- Wei, Y.B.; Liu, J.J.; Villaescusa, J.C.; Åberg, E.; Brené, S.; Wegener, G.; Mathé, A.A.; Lavebratt, C. Elevation of Il6 is associated with disturbed let-7 biogenesis in a genetic model of depression. Transl. Psychiatry 2016, 6, e869. [Google Scholar] [CrossRef] [Green Version]
- Kyle, R.A.; Rajkumar, S.V. Multiple myeloma. N. Engl. J. Med. 2004, 351, 1860–1873. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.Y.; Li, Y.C.; Geng, C.Y.; Wang, H.J.; Chen, W.M. Potential Relationship between Clinical Significance and Serum Exosomal miRNAs in Patients with Multiple Myeloma. Biomed. Res. Int. 2019, 2019, 1575468. [Google Scholar] [CrossRef]
- Chesi, M.; Robbiani, D.F.; Sebag, M.; Chng, W.J.; Affer, M.; Tiedemann, R.; Valdez, R.; Palmer, S.E.; Haas, S.S.; Stewart, A.K.; et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008, 13, 167–180. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gabrea, A.; Bergsagel, P.L.; Kuehl, W.M. Distinguishing primary and secondary translocations in multiple myeloma. DNA Repair 2006, 5, 1225–1233. [Google Scholar] [CrossRef] [PubMed]
- Avet-Loiseau, H.; Gerson, F.; Magrangeas, F.; Minvielle, S.; Harousseau, J.L.; Bataille, R. Intergroupe Francophone du Myélome. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001, 98, 3082–3086. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhou, Q.; Dong, J.; Luo, R.; Zhou, X.; Wang, J.; Chen, F. MicroRNA-20a regulates cell proliferation, apoptosis and autophagy by targeting thrombospondin 2 in cervical cancer. Eur. J. Pharmacol. 2019, 844, 102–109. [Google Scholar] [CrossRef]
- Mello-Grand, M.; Gregnanin, I.; Sacchetto, L.; Ostano, P.; Zitella, A.; Bottoni, G.; Oderda, M.; Marra, G.; Munegato, S.; Pardini, B.; et al. Circulating microRNAs combined with PSA for accurate and non-invasive prostate cancer detection. Carcinogenesis 2019, 40, 246–253. [Google Scholar] [CrossRef] [PubMed]
- Navarro, A.; Díaz, T.; Tovar, N.; Pedrosa, F.; Tejero, R.; Cibeira, M.T.; Magnano, L.; Rosiñol, L.; Monzó, M.; Bladé, J.; et al. A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget 2015, 6, 1874–1883. [Google Scholar] [CrossRef] [Green Version]
- Yang, W.-C.; Lin, S.-F. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. BioMed Res. Int. 2015, 2015, 341430. [Google Scholar] [CrossRef] [Green Version]
- Jagannathan, S.; Vad, N.; Vallabhapurapu, S.; Vallabhapurapu, S.; Anderson, K.C.; Driscoll, J.J. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib. Leukemia 2015, 29, 727–738. [Google Scholar] [CrossRef]
- Amodio, N.; Di Martino, M.T.; Foresta, U.; Leone, E.; Lionetti, M.; Leotta, M.; Gullà, A.M.; Pitari, M.R.; Conforti, F.; Rossi, M.; et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis. 2012, 3, e436. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, J.H.; Zhou, W.W.; Liu, B.X.; Man, D.L.; Yang, Z.D.; Liu, F.R.; Shang, H. Expression and significance of miR-21 in multiple myeloma patients. Genet. Mol. Res. GMR 2016, 15. [Google Scholar] [CrossRef] [PubMed]
- Zhang, L.; Pan, L.; Xiang, B.; Zhu, H.; Wu, Y.; Chen, M.; Guan, P.; Zou, X.; Valencia, C.A.; Dong, B.; et al. Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma. Oncotarget 2016, 7, 30876–30891. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Greenstein, S.; Krett, N.L.; Kurosawa, Y.; Ma, C.; Chauhan, D.; Hideshima, T.; Anderson, K.C.; Rosen, S.T. Characterization of the MM.1 human multiple myeloma (MM) cell lines: A model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp. Hematol. 2003, 31, 271–282. [Google Scholar] [CrossRef]
- Palagani, A.; Op de Beeck, K.; Naulaerts, S.; Diddens, J.; Sekhar Chirumamilla, C.; Van Camp, G.; Laukens, K.; Heyninck, K.; Gerlo, S.; Mestdagh, P.; et al. Ectopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cells. PLoS ONE 2014, 9, e113842. [Google Scholar] [CrossRef] [PubMed]
- Zhao, J.-J.; Chu, Z.-B.; Hu, Y.; Lin, J.; Wang, Z.; Jiang, M.; Chen, M.; Wang, X.; Kang, Y.; Zhou, Y.; et al. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. Cancer Res. 2015, 75, 4384–4397. [Google Scholar] [CrossRef] [Green Version]
- Gullà, A.; Di Martino, M.T.; Gallo Cantafio, M.E.; Morelli, E.; Amodio, N.; Botta, C.; Pitari, M.R.; Lio, S.G.; Britti, D.; Stamato, M.A.; et al. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2016, 22, 1222–1233. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seckinger, A.; Meißner, T.; Moreaux, J.; Benes, V.; Hillengass, J.; Castoldi, M.; Zimmermann, J.; Ho, A.D.; Jauch, A.; Goldschmidt, H.; et al. miRNAs in multiple myeloma—A survival relevant complex regulator of gene expression. Oncotarget 2015, 6, 39165–39183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Saki, N.; Abroun, S.; Hajizamani, S.; Rahim, F.; Shahjahani, M. Association of Chromosomal Translocation and MiRNA Expression with The Pathogenesis of Multiple Myeloma. Cell J. 2014, 16, 99–110. [Google Scholar]
- Catuogno, S.; Di Martino, M.T.; Nuzzo, S.; Esposito, C.L.; Tassone, P.; de Franciscis, V. An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery. Mol. Ther. Nucleic Acids 2019, 18, 981–990. [Google Scholar] [CrossRef] [Green Version]
- Ribatti, D.; Vacca, A.; Einsele, H. Targeting B-cell non Hodgkin lymphoma: New and old tricks. Leuk. Res. 2016, 42, 93–104. [Google Scholar] [CrossRef]
- Caracciolo, D.; Montesano, M.; Altomare, E.; Scionti, F.; Di Martino, M.T.; Tagliaferri, P.; Tassone, P. The potential role of miRNAs in multiple myeloma therapy. Expert Rev. Hematol. 2018, 11, 793–803. [Google Scholar] [CrossRef] [PubMed]
- Rögnvaldsson, S.; Love, T.J.; Thorsteinsdottir, S.; Reed, E.R.; Óskarsson, J.Þ.; Pétursdóttir, Í.; Sigurðardóttir, G.Á.; Viðarsson, B.; Önundarson, P.T.; Agnarsson, B.A.; et al. Iceland screens, treats, or prevents multiple myeloma (iStopMM): A population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021, 11, 94. [Google Scholar] [CrossRef]
- Shaughnessy, J.; Jacobson, J.; Sawyer, J.; McCoy, J.; Fassas, A.; Zhan, F.; Bumm, K.; Epstein, J.; Anaissie, E.; Jagannath, S.; et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: Interpretation in the context of global gene expression. Blood 2003, 101, 3849–3856. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Barlogie, B.; Tricot, G.; Rasmussen, E.; Anaissie, E.; van Rhee, F.; Zangari, M.; Fassas, A.; Hollmig, K.; Pineda-Roman, M.; Shaughnessy, J.; et al. Total therapy 2 without thalidomide in comparison with total therapy 1: Role of intensified induction and posttransplantation consolidation therapies. Blood 2006, 107, 2633–2638. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhan, F.; Barlogie, B.; Arzoumanian, V.; Huang, Y.; Williams, D.R.; Hollmig, K.; Pineda-Roman, M.; Tricot, G.; van Rhee, F.; Zangari, M.; et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007, 109, 1692–1700. [Google Scholar] [CrossRef] [Green Version]
- Khan, R.; Dhodapkar, M.; Rosenthal, A.; Heuck, C.; Papanikolaou, X.; Qu, P.; van Rhee, F.; Zangari, M.; Jethava, Y.; Epstein, J.; et al. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica 2015, 100, 1214–1221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
miRNA | miRNA Modulation | Effect on Myeloma Pathogenesis | Target | References |
---|---|---|---|---|
Let-7a Let-7b | Related to disease initiation, progression | MYC in t(11;14) | [12] | |
miRNA-34a | Inhibited cell proliferation, colony formation, and increased cancer stem cells apoptosis | TGIF2 | [14,41] | |
miRNA-15a/ miRNA 16 | Enhanced proliferation in MM | AKT3, ribosomal protein S6, MAPK, NF-kB, MAP3K1 | [12,40] | |
miRNA-21 | Enhanced cell survival | STAT3 PTEN, BIM and p21 | [34] [37] | |
miRNA-134-5p, miRNA-107, miRNA 15a-5 | Enhanced cell proliferation in MGUS and MM | ITGB1, PIK3R1 | [36] | |
miRNA-17-92 | Decreased apoptosis in MM | PTEN, E2F1, Bcl2/ BIM | [37] | |
miRNA-181 a/b | Enhanced cell proliferation, cell cycle, apoptosis and invasion in MM | p53, PCAF, NOVA1 | [37,42] | |
miRNA-375 | Enhanced cell survival and proliferation both in MGUS and MM | PDK1 | [43] | |
miRNA-19a, miRNA 19b | Increased, constitutive JAK/STAT3 activation | SOCS-1 | [44] | |
miRNA-32 | p53 function interference in MM | PCAF | [45] | |
miRNA106-b, miRNA-93, miRNA-25 | Increased in MGUS and MM; enhanced cell survival | PCAF | [46] |
Biochemical Parameter | miRNA | Parameter/miRNA Correlation | MM Correlation | Ref. |
---|---|---|---|---|
M-protein | miRNA-1246 | Negative | MM vs. HD | [13] |
C-reactive protein (CRP) | miRNA-744 | Negative | MM vs. HD | [14] |
let-7e | Negative | |||
Albumin (ALB) | let-7d | Positive | MM vs. HD MM vs. HD | [14] [48] |
let-7e | Positive | |||
miRNA-34a | Negative | |||
miRNA-744 | Positive | |||
lactic acid dehydrogenase (LDH) | miRNA-202 | Negative | MM vs. HD MM vs. HD MM vs. HD | [36,81] |
miRNA-34a-5p | Negative | |||
miRNA-107 | Negative | |||
Thrombocyte counts | miRNA-744 | Positive | MM vs. HD | [48] |
miRNA-130a | Positive | |||
let-7d | Positive | |||
let-7e | Positive | |||
β2-microglobulin (β2-MG) | miRNA-744 | Negative | ||
miRNA-130a | Negative | |||
let-7d | Negative | |||
let-7e | Negative | |||
miRNA-202 | Positive | |||
let-7c-5p | Negative | |||
miRNA-140-3p | Negative | |||
miRNA-185-5p | Negative | |||
miRNA-425-5p | Negative | |||
Creatinine (Cr) | miRNA-744 | Negative | MM vs. HD MM vs. HD | [48] [85] |
miRNA-130a | Negative | |||
let-7d | Negative | |||
let-7e | Negative | |||
let-7c-5p | Negative | |||
miRNA-140-3p | Negative | |||
miRNA-185-5p | Negative | |||
miRNA-425-5p | Negative | |||
Kappa light chain | miRNA-202 | Positive | MM vs. HD | [81] |
Lambda light chain | miRNA-202 | Negative | MM vs. HD | [81] |
IL-6 | let-7 | Negative | MM vs. HD | [85] |
let-7c-5p | Negative | |||
miRNA-140-3p | Negative | |||
miRNA-185-5p | Negative | |||
miRNA-425-5p | Negative | |||
β-CTX | let-7c-5p | Negative | MM vs. HD | [85] |
miRNA-140-3p | Negative | |||
miRNA-185-5p | Negative | |||
miRNA-425-5p | Negative |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Desantis, V.; Solimando, A.G.; Saltarella, I.; Sacco, A.; Giustini, V.; Bento, M.; Lamanuzzi, A.; Melaccio, A.; Frassanito, M.A.; Paradiso, A.; et al. MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease. Cancers 2021, 13, 3650. https://doi.org/10.3390/cancers13153650
Desantis V, Solimando AG, Saltarella I, Sacco A, Giustini V, Bento M, Lamanuzzi A, Melaccio A, Frassanito MA, Paradiso A, et al. MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease. Cancers. 2021; 13(15):3650. https://doi.org/10.3390/cancers13153650
Chicago/Turabian StyleDesantis, Vanessa, Antonio Giovanni Solimando, Ilaria Saltarella, Antonio Sacco, Viviana Giustini, Marta Bento, Aurelia Lamanuzzi, Assunta Melaccio, Maria Antonia Frassanito, Angelo Paradiso, and et al. 2021. "MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease" Cancers 13, no. 15: 3650. https://doi.org/10.3390/cancers13153650